Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice
Dinnon, Kenneth H. , Leist, Sarah R. , Dang, Hong , Fritch, Ethan J. , Gully, Kendra L. , Cruz, Gabriela De la , Evangelista, Mia D. , Asakura, Takanori , Gilmore, Rodney C. , Hawkins, Padraig, Nakano, Satoko , West, Ande , Schäfer, Alexandra, Gralinski, Lisa E. , Zweigart, Mark R. , Dong, Stephanie , McBride, Jennifer , Cooley, Michelle R. , Hines, Jesse B., Love, Miriya K., Groshong, Steve D. , VanSchoiack, Alison , Phelan, Stefan, Liang, Yan , Hether, Tyler , Zumwalt, Ross E., Barton, Lisa M., Duval, Eric J., Stroberg, Edana , Borczuk, Alain , Thorne, Leigh B., Sakthivel, Muthu , Lee, Yueh Z. , Mock, Jason R. , Seibold, Max A. , O’Neal, Wanda K. , Montgomery, Stephanie A. , Boucher, Richard C. , Okuda, Kenichi , Dang, Hong , Fritch, Ethan J , Gully, Kendra L , De la Cruz, Gabriela , Evangelista, Mia D , Asakura, Takanori , Gilmore, Rodney C , Nakano, Satoko , West, Ande , Schäfer, Alexandra , Gralinski, Lisa E , Everman, Jamie L , Sajuthi, Satria P , Dong, Stephanie , McBride, Jennifer , Cooley, Michelle R , Groshong, Steve D , VanSchoiack, Alison , Phelan, Stefan J , Liang, Yan , Hether, Tyler , Leon, Michael , Sakthivel, Muthu K , Lee, Yueh Z , Hagood, James S , Mock, Jason R , Seibold, Max A , O'Neal, Wanda K , Montgomery, Stephanie A , Boucher, Richard C , Baric, Ralph S , Mukhopadhyay, Sanjay

Mayo Clinic

Science Translational Medicine | July 7, 2022 | Volume: 14 | Issue: 664 | Pages: No page available

10.1126/scitranslmed.abo5070 | PMID 35857635 Get It

A subset of individuals who recover from coronavirus disease 2019 (COVID-19) develop post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PASC), but the mechanistic basis of PASC-associated lung abnormalities suffers from a lack of longitudinal tissue samples. The mouse-adapted SARS-CoV-2 strain MA10 produces an acute respiratory distress syndrome in mice similar to humans. To investigate PASC pathogenesis, studies of MA10-infected mice were extended from acute to clinical recovery phases. At 15 to 120 days after virus clearance, pulmonary histologic findings included subpleural lesions composed of collagen, proliferative fibroblasts, and chronic inflammation, including tertiary lymphoid structures. Longitudinal spatial transcriptional profiling identified global reparative and fibrotic pathways dysregulated in diseased regions, similar to human COVID-19. Populations of alveolar intermediate cells, coupled with focal up-regulation of profibrotic markers, were identified in persistently diseased regions. Early intervention with antiviral EIDD-2801 reduced chronic disease, and early antifibrotic agent (nintedanib) intervention modified early disease severity. This murine model provides opportunities to identify pathways associated with persistent SARS-CoV-2 pulmonary disease and test countermeasures to ameliorate PASC.
Inflammatory biomarkers, multi-morbidity, and biologic aging
Rocca, Walter A. , Jacobson, Debra J., McGree, Michaela E. , St Sauver, Jennifer L , Rocca, Walter, LeBrasseur, Nathan, Chamberlain, Alanna, Jacobson, Debra, McGree, Michaela, Mielke, Michelle, Sauver, Jennifer L. St. , LeBrasseur, Nathan K. , Chamberlain, Alanna M. , Olson, Janet E. , Mielke, Michelle M.

Mayo Clinic

Journal of International Medical Research | July 7, 2022 | Volume: 50 | Issue: 7 | Pages: No page available

10.1177/03000605221109393 | PMID 35796512 Get It

Objectives To study the association between multi-morbidity percentiles, which is a measure of clinical aging, and interleukin (IL)-6, IL-10, and tumor necrosis factor (TNF)-α. Methods Participants 50 to 95 years of age from the Mayo Clinic Study of Aging were assigned age- and sex-specific multi-morbidity percentiles using look-up tables that were reported previously (n = 1646). Percentiles were divided into quintiles for analysis. Plasma IL-6, IL-10, and TNF-α levels were measured in 1595 participants. Median inflammatory marker levels were compared across multi-morbidity quintiles using nonparametric tests. Results People with higher multi-morbidity percentiles had significantly higher IL-6 and TNF-α levels compared with those with lower multi-morbidity percentiles. Tests for trend across five multi-morbidity quintiles were significant among women for IL-6 and among participants 70 years of age or older for IL-6 and TNF-α. IL-10 was not associated with multi-morbidity percentiles. Conclusions Multi-morbidity percentiles may be a useful clinical index of biological age for future studies, particularly in women and people 70 years of age and older.
Skeletal Effects of Inducible ERα Deletion in Osteocytes in Adult Mice
Doolittle, Madison L. , Saul, Dominik , Kaur, Japneet , Rowsey, Jennifer L. , Eckhardt, Brittany, Vos, Stephanie J. B. , Grain, Sarah, Kroupova, Kveta, Ruan, Ming, Weivoda, Megan , Oursler, Merry Jo, Vos, Stephanie, Farr, Joshua N , Monroe, David G , Khosla, Sundeep , Saul, Dominik , Vos, Stephanie, Farr, Joshua N. , Monroe, David G. , Khosla, Sundeep

Mayo Clinic

Journal of Bone and Mineral Research | July 5, 2022 | Volume: 37 | Issue: 9 | Pages: 1750-1760

10.1002/jbmr.4644 | PMID 35789113 Get It

ABSTRACT Estrogen is known to regulate bone metabolism in both women and men, but substantial gaps remain in our knowledge of estrogen and estrogen receptor alpha (ERα) regulation of adult bone metabolism. Studies using global ERα-knockout mice were confounded by high circulating sex-steroid levels, and osteocyte/osteoblast-specific ERα deletion may be confounded by ERα effects on growth versus the adult skeleton. Thus, we developed mice expressing the tamoxifen-inducible CreERT2 in osteocytes using the 8-kilobase (kb) Dmp1 promoter (Dmp1CreERT2). These mice were crossed with ERαfl//fl mice to create ERαΔOcy mice, permitting inducible osteocyte-specific ERα deletion in adulthood. After intermittent tamoxifen treatment of adult 4-month-old mice for 1 month, female, but not male, ERαΔOcy mice exhibited reduced spine bone volume fraction (BV/TV (−20.1%, p = 0.004) accompanied by decreased trabecular bone formation rate (−18.9%, p = 0.0496) and serum P1NP levels (−38.9%, p = 0.014). Periosteal (+65.6%, p = 0.004) and endocortical (+64.1%, p = 0.003) expansion were higher in ERαΔOcy mice compared to control (Dmp1CreERT2) mice at the tibial diaphysis, reflecting the known effects of estrogen to inhibit periosteal apposition and promote endocortical formation. Increases in Sost (2.1-fold, p = 0.001) messenger RNA (mRNA) levels were observed in trabecular bone at the spine in ERαΔOcy mice, consistent with previous reports that estrogen deficiency is associated with increased circulating sclerostin as well as bone SOST mRNA levels in humans. Further, the biological consequences of increased Sost expression were reflected in significant overall downregulation in panels of osteoblast and Wnt target genes in osteocyte-enriched bones from ERαΔOcy mice. These findings thus establish that osteocytic ERα is critical for estrogen action in female, but not male, adult bone metabolism. Moreover, the reduction in bone formation accompanied by increased Sost, decreased osteoblast, and decreased Wnt target gene expression in ERαΔOcy mice provides a direct link in vivo between ERα and Wnt signaling. © 2022 American Society for Bone and Mineral Research (ASBMR).
Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions
Agüera-Ortíz, Luis , Bruneau, Marie‐Andrée , Creese, Byron , D’Antonio, Fabrizia , Ismail, Zahinoor , Mortby, Moyra E. , Núñez, Nicolás A. , Oliveira, Fabricio Ferreira de , Pereiro, Arturo X. , Ravona‐Springer, Ramit , Rouse, Hillary J , Wang, Huali , Babulal, Ganesh M. , Fischer, Corinne Eleanor , Gatchel, Jennifer R. , Kumar, Sanjeev , McGeown, William J. , Lanctôt, Krista L.

Mayo Clinic

Journal of Alzheimer’s Disease | July 1, 2022 | Volume: 88 | Issue: 4 | Pages: 1203-1228

10.3233/jad-215483 | PMID 35786651 Get It

Psychotic phenomena are among the most severe and disruptive symptoms of dementias and appear in 30% to 50% of patients. They are associated with a worse evolution and great suffering to patients and caregivers. Their current treatments obtain limited results and are not free of adverse effects, which are sometimes serious. It is therefore crucial to develop new treatments that can improve this situation. We review available data that could enlighten the future design of clinical trials with psychosis in dementia as main target. Along with an explanation of its prevalence in the common diseases that cause dementia, we present proposals aimed at improving the definition of symptoms and what should be included and excluded in clinical trials. A review of the available information regarding the neurobiological basis of symptoms, in terms of pathology, neuroimaging, and genomics, is provided as a guide towards new therapeutic targets. The correct evaluation of symptoms is transcendental in any therapeutic trial and these aspects are extensively addressed. Finally, a critical overview of existing pharmacological and non-pharmacological treatments is made, revealing the unmet needs, in terms of efficacy and safety. Our work emphasizes the need for better definition and measurement of psychotic symptoms in dementias in order to highlight their differences with symptoms that appear in non-dementing diseases such as schizophrenia. Advances in neurobiology should illuminate the development of new, more effective and safer molecules for which this review can serve as a roadmap in the design of future clinical trials.
Body weight changes and associated predictors in a prospective cohort of young breast cancer survivors
Sella, Tal , Tan‐Wasielewski, Zhenying, Rosenberg, Shoshana M. , Poorvu, Philip D. , Tayob, Nabihah , Ruddy, Kathryn J. , Gelber, Shari , Schapira, Lidia , Come, Steven E. , Peppercorn, Jeffrey , Ligibel, Jennifer A. , Rosenberg, Shoshana , Ruddy, Kathryn J , Schapira, Lidia , Partridge, Ann H , Zheng, Yue , Tamimi, Rulla M. , Borges, Virginia F. , Partridge, Ann H.

Mayo Clinic

Cancer | July 1, 2022 | Volume: 128 | Issue: 17 | Pages: 3158-3169

10.1002/cncr.34342 | PMID 35775874 Get It

BackgroundWeight gain after a breast cancer diagnosis is common and is associated with inferior outcomes. Young survivors may be especially susceptible to weight changes given the impact of treatment on menopausal status.MethodsThe authors identified women who were diagnosed with stage 0 to III breast cancer at age 40 years or younger between 2006 and 2016 from a multicenter prospective cohort. Self‐reported weight was collected at diagnosis and at 1 year and 3 years postdiagnosis. Tumor and treatment data were obtained from medical records and patient surveys. Multinomial logistic regression was used to identify the factors associated with weight gain (≥5%) or weight loss (≥5%) versus stable weight at 1 year and 3 years postdiagnosis.ResultsThe cohort included 956 women with a median age of 37 years at diagnosis. Mean weight significantly increased over time from 66.54 ± 14.85 kg at baseline to 67.33 ± 15.53 and 67.77 ± 14.65 kg at 1 year and 3 years, respectively (p ≤ .001 for both comparisons). The proportion of women experiencing ≥5% weight gain increased from 24.8% at 1 year to 33.9% at 3 years. At 1 year, less self‐perceived financial comfort, Black race, and stage III disease were significantly associated with weight gain; at 3 years, only less self‐perceived financial comfort remained significant. Baseline overweight or obesity was significantly associated with weight loss at both time points. Chemotherapy, endocrine therapy, and treatment‐related menopause were not associated with weight change.ConclusionsOne third of young breast cancer survivors experienced clinically significant weight gain 3 years after diagnosis; however, treatment‐related associations were not observed. Age‐appropriate lifestyle interventions, including the reduction of financial barriers, are needed to prevent weight gain in this high‐risk population.
Health Impairments in Children and Adolescents After Hospitalization for Acute COVID-19 or MIS-C
Berbert, Laura , Young, Cameron C. , Feldstein, Leora R. , Zambrano, Laura D. , Kücükak, Suden, Newhams, Margaret M. , Miller, Kristen , FitzGerald, Madyson M., He, Jie , Halasa, Natasha , Loftis, Laura L. , Walker, Tracie C. , Gertz, Shira J. , Tarquinio, Keiko M. , Fitzgerald, Julie C. , Kong, Michele , Schuster, Jennifer E. , Mack, Elizabeth H. , Rowan, Courtney M. , Staat, Mary Allen , Zinter, Matt S. , Irby, Katherine , Crandall, Hillary , Flori, Heidi R. , Cullimore, Melissa L. , Nofziger, Ryan A. , Gaspers, Mary Glas , Hume, Janet R. , Levy, Emily R. , Chen, Sabrina , Patel, Manish M. , Weller, Edie, Campbell, Angela P. , Randolph, Adrienne G. , Investigators, for the Overcoming COVID-19, Martin, Lora , Malloch, Lacy , Levy, Emily R , Young, Cameron C , Randolph, Adrienne G , Kong, Michele , Hume, Janet R , Staat, Mary A , Gertz, Shira J , Maddux, Aline B. , Miller, Kristen R. , Cvijanovich, Natalie Z , Schwartz, Stephanie P. , Hobbs, Charlotte V. , Shein, Steven L. , Tenforde, Mark W. , Investigators, for the Overcoming COVID-19

Mayo Clinic

Pediatrics | June 29, 2022 | Volume: 150 | Issue: 3 | Pages: No page available

10.1542/peds.2022-057798 | PMID 35765138 Get It

OBJECTIVES To evaluate risk factors for postdischarge sequelae in children and adolescents hospitalized for acute coronavirus disease 2019 (COVID-19) or multisystem inflammatory syndrome in children (MIS-C). METHODS Multicenter prospective cohort study conducted in 25 United States pediatric hospitals. Patients <21-years-old, hospitalized May 2020 to May 2021 for acute COVID-19 or MIS-C with follow-up 2 to 4 months after admission. We assessed readmissions, persistent symptoms or activity impairment, and new morbidities. Multivariable regression was used to calculate adjusted risk ratios (aRR) and 95% confidence intervals (CI). RESULTS Of 358 eligible patients, 2 to 4 month survey data were available for 119 of 155 (76.8%) with acute COVID-19 and 160 of 203 (78.8%) with MIS-C. Thirteen (11%) patients with acute COVID-19 and 12 (8%) with MIS-C had a readmission. Thirty-two (26.9%) patients with acute COVID-19 had persistent symptoms (22.7%) or activity impairment (14.3%) and 48 (30.0%) with MIS-C had persistent symptoms (20.0%) or activity impairment (21.3%). For patients with acute COVID-19, persistent symptoms (aRR, 1.29 [95% CI, 1.04–1.59]) and activity impairment (aRR, 1.37 [95% CI, 1.06–1.78]) were associated with more organ systems involved. Patients with MIS-C and pre-existing respiratory conditions more frequently had persistent symptoms (aRR, 3.09 [95% CI, 1.55–6.14]) and those with obesity more frequently had activity impairment (aRR, 2.52 [95% CI, 1.35–4.69]). New morbidities were infrequent (9% COVID-19, 1% MIS-C). CONCLUSIONS Over 1 in 4 children hospitalized with acute COVID-19 or MIS-C experienced persistent symptoms or activity impairment for at least 2 months. Patients with MIS-C and respiratory conditions or obesity are at higher risk of prolonged recovery.
The Multistage Antimalarial Compound Calxinin Perturbates P. falciparum Ca2+ Homeostasis by Targeting a Unique Ion Channel
Gupta, Yash , Sharma, Neha , Singh, Snigdha , Romero, Jesús G., Rajendran, Vinoth , Mogire, Reagan M. , Kashif, Mohammad , Jeske, Walter , Poonam, Poonam , Ogutu, Bernhards , Kanzok, Stefan M. , Akala, Hoseah M. , Legac, Jennifer, Rosenthal, Philip J., Rademacher, David J., Durvasula, Ravi , Singh, Agam Prasad , Rathi, Brijesh , Kempaiah, Prakasha , Poonam , Akala, Hoseah M , Singh, Agam P , Rathi, Brijesh , Kempaiah, Prakasha , Gupta, Yash , Beach, Jordan R. , Rosenthal, Philip Jon

Mayo Clinic

Pharmaceutics | June 29, 2022 | Volume: 14 | Issue: 7 | Pages: 1371

10.3390/pharmaceutics14071371 | PMID 35890267 Get It

Malaria elimination urgently needs novel antimalarial therapies that transcend resistance, toxicity, and high costs. Our multicentric international collaborative team focuses on developing multistage antimalarials that exhibit novel mechanisms of action. Here, we describe the design, synthesis, and evaluation of a novel multistage antimalarial compound, ‘Calxinin’. A compound that consists of hydroxyethylamine (HEA) and trifluoromethyl-benzyl-piperazine. Calxinin exhibits potent inhibitory activity in the nanomolar range against the asexual blood stages of drug-sensitive (3D7), multidrug-resistant (Dd2), artemisinin-resistant (IPC4912), and fresh Kenyan field isolated Plasmodium falciparum strains. Calxinin treatment resulted in diminished maturation of parasite sexual precursor cells (gametocytes) accompanied by distorted parasite morphology. Further, in vitro liver-stage testing with a mouse model showed reduced parasite load at an IC50 of 79 nM. A single dose (10 mg/kg) of Calxinin resulted in a 30% reduction in parasitemia in mice infected with a chloroquine-resistant strain of the rodent parasite P. berghei. The ex vivo ookinete inhibitory concentration within mosquito gut IC50 was 150 nM. Cellular in vitro toxicity assays in the primary and immortalized human cell lines did not show cytotoxicity. A computational protein target identification pipeline identified a putative P. falciparum membrane protein (Pf3D7_1313500) involved in parasite calcium (Ca2+) homeostasis as a potential Calxinin target. This highly conserved protein is related to the family of transient receptor potential cation channels (TRP-ML). Target validation experiments showed that exposure of parasitized RBCs (pRBCs) to Calxinin induces a rapid release of intracellular Ca2+ from pRBCs; leaving de-calcinated parasites trapped in RBCs. Overall, we demonstrated that Calxinin is a promising antimalarial lead compound with a novel mechanism of action and with potential therapeutic, prophylactic, and transmission-blocking properties against parasites resistant to current antimalarials.
SHP2 inhibition enhances Yes-associated protein–mediated liver regeneration in murine partial hepatectomy models
Watkins, Ryan , Buckarma, EeeLN H. , Tomlinson, Jennifer L. , McCabe, Chantal E. , Yonkus, Jennifer A. , Werneburg, Nathan W., Bayer, Rachel L., Starlinger, Patrick , Robertson, Keith D. , Wang, Chen , Smoot, Rory L. , Smoot, Rory L , Robertson, Keith D , Wang, Chen , Starlinger, Patrick , Yonkus, Jennifer A , Buckarma, EeeLN , Tomlinson, Jennifer , Gores, Gregory J.

Mayo Clinic

JCI Insight | June 28, 2022 | Volume: 7 | Issue: 15 | Pages: No page available

10.1172/jci.insight.159930 | PMID 35763355 Get It

Disrupted liver regeneration following hepatectomy represents an “undruggable” clinical challenge associated with poor patient outcomes. Yes-associated protein (YAP), a transcriptional coactivator that is repressed by the Hippo pathway, is instrumental in liver regeneration. We have previously described an alternative, Hippo-independent mechanism of YAP activation mediated by downregulation of protein tyrosine phosphatase nonreceptor type 11 (PTPN11, also known as SHP2) inhibition. Herein, we examined the effects of YAP activation with a selective SHP1/SHP2 inhibitor, NSC-87877, on liver regeneration in murine partial hepatectomy models. In our studies, NSC-87877 led to accelerated hepatocyte proliferation, improved liver regeneration, and decreased markers of injury following partial hepatectomy. The effects of NSC-87877 were lost in mice with hepatocyte-specific Yap/Taz deletion, and this demonstrated dependence on these molecules for the enhanced regenerative response. Furthermore, administration of NSC-87877 to murine models of nonalcoholic steatohepatitis was associated with improved survival and decreased markers of injury after hepatectomy. Evaluation of transcriptomic changes in the context of NSC-87877 administration revealed reduction in fibrotic signaling and augmentation of cell cycle signaling. Cytoprotective changes included downregulation of Nr4a1 , an apoptosis inducer. Collectively, the data suggest that SHP2 inhibition induces a pro-proliferative and cytoprotective enhancement of liver regeneration dependent on YAP.
Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components
Snyder, Edward L. , Wheeler, Allison P. , Refaai, Majed A. , Cohn, Claudia S. , Poisson, Jessica , Fontaine, Magali J. , Sehl, Mary E. , Uhl, Lynne , Spinella, Philip C. , Fenelus, Maly , Coyle, Thomas, Becker, Joanne , Jeng, Michael , Spencer, Bryan R. , Young, Pampee P. , OʼBrien, Jennifer , Schiller, Gary J. , Roback, John D. , Malynn, Elizabeth, Jackups, Ronald , Avecilla, Scott T. , Lin, Jin‐Sying, Bentow, Stanley, Peng, Ho‐Lan, Varrone, Jeanne, Fontaine, Magali , Spinella, Philip C , Gehrie, Eric A , Spencer, Bryan R , Young, Pampee , O'Brien, Jennifer J, Avecilla, Scott T , Benjamin, Richard J , Corash, Laurence M , Cohn, Claudia S , Wheeler, Allison P , Jeng, Michael , Nooka, Ajay K. , Liles, Darla , Johnson, Andrew, Liu, Kathy

Mayo Clinic

Transfusion | June 24, 2022 | Volume: 62 | Issue: 7 | Pages: 1365-1376

10.1111/trf.16987 | PMID 35748490 Get It

AbstractBackgroundPlatelet transfusion carries risk of transfusion‐transmitted infection (TTI). Pathogen reduction of platelet components (PRPC) is designed to reduce TTI. Pulmonary adverse events (AEs), including transfusion‐related acute lung injury and acute respiratory distress syndrome (ARDS) occur with platelet transfusion.Study designAn open label, sequential cohort study of transfusion‐dependent hematology‐oncology patients was conducted to compare pulmonary safety of PRPC with conventional PC (CPC). The primary outcome was the incidence of treatment‐emergent assisted mechanical ventilation (TEAMV) by non‐inferiority. Secondary outcomes included: time to TEAMV, ARDS, pulmonary AEs, peri‐transfusion AE, hemorrhagic AE, transfusion reactions (TRs), PC and red blood cell (RBC) use, and mortality.ResultsBy modified intent‐to‐treat (mITT), 1068 patients received 5277 PRPC and 1223 patients received 5487 CPC. The cohorts had similar demographics, primary disease, and primary therapy. PRPC were non‐inferior to CPC for TEAMV (treatment difference −1.7%, 95% CI: (−3.3% to −0.1%); odds ratio = 0.53, 95% CI: (0.30, 0.94). The cumulative incidence of TEAMV for PRPC (2.9%) was significantly less than CPC (4.6%, p = .039). The incidence of ARDS was less, but not significantly different, for PRPC (1.0% vs. 1.8%, p = .151; odds ratio = 0.57, 95% CI: (0.27, 1.18). AE, pulmonary AE, and mortality were not different between cohorts. TRs were similar for PRPC and CPC (8.3% vs. 9.7%, p = .256); and allergic TR were significantly less with PRPC (p = .006). PC and RBC use were not increased with PRPC.DiscussionPRPC demonstrated reduced TEAMV with no excess treatment‐related pulmonary morbidity.
Incidence and management of pleural effusions in patients with Wilms tumor: A Pediatric Surgical Oncology Research Collaborative study
Al‐Hadidi, Ameer , Rinehardt, Hannah , Sutthatarn, Pattamon , Condon, Sienna, Chen, Stephanie , Wong‐Michalak, Shannon , Short, Scott S. , Meyers, Rebecka L. , Johnston, Michael E. , Zens, Tiffany , Dasgupta, Roshni , Calabro, Kristen , Piché, Nelson , Callas, Hannah, McKay, Katlyn G. , Lovvorn, Harold N. , Tracy, Elisabeth T. , Lund, Sarah , Polites, Stephanie F. , Davidson, Jacob , Dhooma, Janel, Seemann, Natashia M. , Marquart, John , Gainer, Haley , Lal, Dave R. , Rich, Barrie S. , Glick, Richard D. , Maloney, Lauren , Radu, Stephani, Fialkowski, Elizabeth , Kwok, Pei En , Romao, Rodrigo , Newman, Erika A. , Diehl, Thomas M. , Polcz, Valerie E., Petroze, Robin T. , Aldrink, Jennifer H. , Lautz, Timothy , Lund, Sarah B, Tracy, Elisabeth T , Aldrink, Jennifer H , Dasgupta, Roshni , Talbot, Lindsay J , Murphy, Andrew J. , Whitlock, Richard S. , Naik‐Mathuria, Bindi , Utria, Alan Fremder , Rothstein, David H. , Kim, Eugene S. , Kastenberg, Zachary J. , Malek, Marcus M. , Lautz, Timothy B. , Commander, Sarah Jane , Radu, Stephanie , Rubalcava, Nathan S. , Ehrlich, Peter F. , Le, Hau D. , Stanek, Joseph

Mayo Clinic

International Journal of Cancer | June 24, 2022 | Volume: 151 | Issue: 10 | Pages: 1696-1702

10.1002/ijc.34188 | PMID 35748343 Get It

AbstractWilms tumor (WT) is the most common renal malignancy in children. Children with favorable histology WT achieve survival rates of over 90%. Twelve percent of patients present with metastatic disease, most commonly to the lungs. The presence of a pleural effusion at the time of diagnosis of WT may be noted on staging imaging; however, minimal data exist regarding the significance and prognostic importance of this finding. The objectives of our study are to identify the incidence of pleural effusions in patients with WT, and to determine the potential impact on oncologic outcomes. A multi‐institutional retrospective review was performed from January 2009 to December 2019, including children with WT and a pleural effusion on diagnostic imaging treated at Pediatric Surgical Oncology Research Collaborative (PSORC) participating institutions. Of 1259 children with a new WT diagnosis, 94 (7.5%) had a pleural effusion. Patients with a pleural effusion were older than those without (median 4.3 vs 3.5 years; P = .004), and advanced stages were more common (local stage III 85.9% vs 51.9%; P < .0001). Only 14 patients underwent a thoracentesis for fluid evaluation; 3 had cytopathologic evidence of malignant cells. Event‐free and overall survival of all children with WT and pleural effusions was 86.2% and 91.5%, respectively. The rate and significance of malignant cells present in pleural fluid is unknown due to low incidence of cytopathologic analysis in our cohort; therefore, the presence of an effusion does not appear to necessitate a change in therapy. Excellent survival can be expected with current stage‐specific treatment regimens.